Department of Medicine, University of Auckland, Private Bag 92 019, Auckland 1142, New Zealand.
BMJ. 2011 Apr 19;342:d2040. doi: 10.1136/bmj.d2040.
To investigate the effects of personal calcium supplement use on cardiovascular risk in the Women's Health Initiative Calcium/Vitamin D Supplementation Study (WHI CaD Study), using the WHI dataset, and to update the recent meta-analysis of calcium supplements and cardiovascular risk.
Reanalysis of WHI CaD Study limited access dataset and incorporation in meta-analysis with eight other studies. Data source WHI CaD Study, a seven year, randomised, placebo controlled trial of calcium and vitamin D (1g calcium and 400 IU vitamin D daily) in 36,282 community dwelling postmenopausal women. Main outcome measures Incidence of four cardiovascular events and their combinations (myocardial infarction, coronary revascularisation, death from coronary heart disease, and stroke) assessed with patient-level data and trial-level data.
In the WHI CaD Study there was an interaction between personal use of calcium supplements and allocated calcium and vitamin D for cardiovascular events. In the 16,718 women (46%) who were not taking personal calcium supplements at randomisation the hazard ratios for cardiovascular events with calcium and vitamin D ranged from 1.13 to 1.22 (P = 0.05 for clinical myocardial infarction or stroke, P = 0.04 for clinical myocardial infarction or revascularisation), whereas in the women taking personal calcium supplements cardiovascular risk did not alter with allocation to calcium and vitamin D. In meta-analyses of three placebo controlled trials, calcium and vitamin D increased the risk of myocardial infarction (relative risk 1.21 (95% confidence interval 1.01 to 1.44), P = 0.04), stroke (1.20 (1.00 to 1.43), P = 0.05), and the composite of myocardial infarction or stroke (1.16 (1.02 to 1.32), P = 0.02). In meta-analyses of placebo controlled trials of calcium or calcium and vitamin D, complete trial-level data were available for 28,072 participants from eight trials of calcium supplements and the WHI CaD participants not taking personal calcium supplements. In total 1384 individuals had an incident myocardial infarction or stroke. Calcium or calcium and vitamin D increased the risk of myocardial infarction (relative risk 1.24 (1.07 to 1.45), P = 0.004) and the composite of myocardial infarction or stroke (1.15 (1.03 to 1.27), P = 0.009).
Calcium supplements with or without vitamin D modestly increase the risk of cardiovascular events, especially myocardial infarction, a finding obscured in the WHI CaD Study by the widespread use of personal calcium supplements. A reassessment of the role of calcium supplements in osteoporosis management is warranted.
利用 WHI 数据集,研究妇女健康倡议钙/维生素 D 补充研究(WHI CaD 研究)中个人钙补充剂使用对心血管风险的影响,并更新最近关于钙补充剂与心血管风险的荟萃分析。
WHI CaD 研究限用数据集的重新分析,并与其他八项研究进行荟萃分析。数据来源:WHI CaD 研究是一项为期 7 年的、随机、安慰剂对照的社区居住绝经后妇女(1g 钙和 400IU 维生素 D 每日)钙和维生素 D(1g 钙和 400IU 维生素 D 每日)的补充试验。
采用患者水平和试验水平数据评估四项心血管事件及其组合(心肌梗死、冠状动脉血运重建、冠心病死亡和中风)的发生率。
在 WHI CaD 研究中,个人使用钙补充剂和分配的钙和维生素 D 与心血管事件之间存在相互作用。在随机分组时未服用个人钙补充剂的 16718 名妇女(46%)中,钙和维生素 D 治疗的心血管事件风险比为 1.13 至 1.22(临床心肌梗死或中风的 P=0.05,临床心肌梗死或血运重建的 P=0.04),而服用个人钙补充剂的妇女,钙和维生素 D 的分配对心血管风险没有影响。在三项安慰剂对照试验的荟萃分析中,钙和维生素 D 增加了心肌梗死的风险(相对风险 1.21(95%置信区间 1.01 至 1.44),P=0.04)、中风(1.20(1.00 至 1.43),P=0.05)和心肌梗死或中风的复合事件(1.16(1.02 至 1.32),P=0.02)。在八项钙补充剂和 WHI CaD 研究中未服用个人钙补充剂的参与者的安慰剂对照试验的荟萃分析中,完全的试验水平数据可用于 28072 名参与者。共有 1384 人发生心肌梗死或中风。钙或钙和维生素 D 增加了心肌梗死的风险(相对风险 1.24(1.07 至 1.45),P=0.004)和心肌梗死或中风的复合事件(1.15(1.03 至 1.27),P=0.009)。
钙补充剂(无论是否含有维生素 D)都能适度增加心血管事件的风险,尤其是心肌梗死的风险,这一发现因 WHI CaD 研究中广泛使用个人钙补充剂而被掩盖。有必要重新评估钙补充剂在骨质疏松症管理中的作用。